For the quarter ending 2025-09-30, KYTX has $187,156K in assets. $35,210K in debts. $34,164K in cash and cash equivalents.
| Balance Sheets | 2025-09-30 | 2025-06-30 | ||
|---|---|---|---|---|
| Cash and cash equivalents | 34,164 | 53,440 | ||
| Available-for-sale marketable securities | 136,974 | 158,237 | ||
| Prepaid expenses and other current assets | 3,787 | 2,650 | ||
| Total current assets | 174,925 | 214,327 | ||
| Restricted cash | 551 | 551 | ||
| Property and equipment, gross | 5,376 | - | ||
| Less accumulated depreciation | 3,583 | - | ||
| Property and equipment, net | 1,793 | 2,162 | ||
| Operating lease right-of-use assets | 4,317 | 5,049 | ||
| Finance lease right-of-use assets | 212 | 366 | ||
| Other non-current assets | 5,358 | 4,053 | ||
| Total assets | 187,156 | 226,508 | ||
| Accounts payable | 3,016 | 9,917 | ||
| Accrued compensation | 6,960 | 4,971 | ||
| Accrued license expense - related party | 6,250 | 6,250 | ||
| Other accrued expenses and current liabilities | 13,960 | 15,075 | ||
| Operating lease liabilities, short-term portion | 3,495 | 3,284 | ||
| Finance lease liabilities, short-term portion | 190 | 292 | ||
| Total current liabilities | 33,871 | 39,789 | ||
| Operating lease liabilities, net of short-term portion | 1,331 | 2,316 | ||
| Finance lease liabilities, net of short-term portion | 8 | 26 | ||
| Total liabilities | 35,210 | 42,131 | ||
| Additional paid-in capital | 538,940 | 534,633 | ||
| Accumulated other comprehensive income | 29 | -20 | ||
| Accumulated deficit | -387,023 | -350,236 | ||
| Total stockholders' equity | 151,946 | 184,377 | ||
| Total liabilities and stockholders' equity | 187,156 | 226,508 | ||
Kyverna Therapeutics, Inc. (KYTX)
Kyverna Therapeutics, Inc. (KYTX)